- Home
- FOXX vs NRXP Comparison
FOXX vs NRXP Comparison
Compare FOXX & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXX
- NRXP
- Stock Information
- Founded
- FOXX 2017
- NRXP 2015
- Country
- FOXX United States
- NRXP United States
- Employees
- FOXX N/A
- NRXP N/A
- Industry
- FOXX
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- FOXX
- NRXP Health Care
- Exchange
- FOXX Nasdaq
- NRXP Nasdaq
- Market Cap
- FOXX 39.6M
- NRXP 32.6M
- IPO Year
- FOXX N/A
- NRXP N/A
- Fundamental
- Price
- FOXX $5.50
- NRXP $3.29
- Analyst Decision
- FOXX
- NRXP Strong Buy
- Analyst Count
- FOXX 0
- NRXP 4
- Target Price
- FOXX N/A
- NRXP $28.50
- AVG Volume (30 Days)
- FOXX 7.6K
- NRXP 284.9K
- Earning Date
- FOXX 08-15-2025
- NRXP 08-13-2025
- Dividend Yield
- FOXX N/A
- NRXP N/A
- EPS Growth
- FOXX N/A
- NRXP N/A
- EPS
- FOXX N/A
- NRXP N/A
- Revenue
- FOXX $53,866,257.00
- NRXP N/A
- Revenue This Year
- FOXX N/A
- NRXP N/A
- Revenue Next Year
- FOXX N/A
- NRXP N/A
- P/E Ratio
- FOXX N/A
- NRXP N/A
- Revenue Growth
- FOXX 3899.98
- NRXP N/A
- 52 Week Low
- FOXX $2.45
- NRXP $1.10
- 52 Week High
- FOXX $12.80
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- FOXX N/A
- NRXP 60.87
- Support Level
- FOXX N/A
- NRXP $3.14
- Resistance Level
- FOXX N/A
- NRXP $3.61
- Average True Range (ATR)
- FOXX 0.00
- NRXP 0.26
- MACD
- FOXX 0.00
- NRXP -0.02
- Stochastic Oscillator
- FOXX 0.00
- NRXP 53.17
About FOXX Foxx Development Holdings Inc. Common Stock
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.